Experts review key updates in LBCL management from the ASH 2022 annual meeting.
EP. 2: CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT StudiesJanuary 27th 2023
In the context of CAR T-cell therapy, Manali Kamdar, MD, reviews TRANSFORM, ZUMA-7, and PILOT trials in the treatment of patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).
EP. 5: Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCLJanuary 28th 2023
Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).
EP. 7: Treatment Sequencing in LBCL: Clinical Trial and Real-World DataFebruary 1st 2023
Experts discuss the role of clinical and real-world data in informing treatment sequencing in patients with large B-cell lymphoma (LBCL) in the academic and community setting.
EP. 8: Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCLFebruary 1st 2023
Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.